Glimulin-MF Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 1mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, contributing to better glucose utilization. The combination is particularly beneficial for patients inadequately controlled on diet and exercise alone or those requiring dual therapy for optimal blood glucose regulation. Glimulin-MF Tablet PR should be administered as per physician’s guidance, typically once or twice daily with meals to minimize gastrointestinal side effects commonly associated with Metformin. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and conditions predisposing to hypoxia. Regular monitoring of blood glucose levels, renal function, and potential adverse effects such as hypoglycemia, lactic acidosis, and gastrointestinal disturbances is essential during therapy. This combination offers a synergistic approach to glycemic management, improving patient compliance through reduced pill burden while effectively controlling blood sugar levels in type 2 diabetes mellitus.